申请人:Hoffman-La Roche Inc.
公开号:US04973599A1
公开(公告)日:1990-11-27
Compounds of the formula ##STR1## wherein n is a integer of 0 to 2; R.sub.1 ' and R.sub.2 ' are, independently, hydrogen, halogen, trifluoromethyl, lower alkoxy or lower alkyl; and X is pyrimidinyl, thiazolyl or ##STR2## wherein R is hydrogen, lower alkyl, aryl or ar-lower alkyl; provided that at least one or R.sub.1 ' and R.sub.2 ' is other than hydrogen, and their pharmaceutically acceptable acid addition salts, and an anti-inflammatory method utilizing a compound of the formula ##STR3## wherein n is an integer of 0 to 2; R.sub.1 and R.sub.2 are, independently, hydrogen, halogen, trifluoromethyl, nitro, amino, lower alkylamino, di-lower-alkylamino, lower alkoxy or lower alkyl; and X is pyrimidinyl, thiazolyl or ##STR4## wherein R is hydrogen, lower alkyl, aryl or ar-lower alkyl; and their pharmaceutically acceptable acid addition salts, are described.
式为##STR1##的化合物,其中n是0到2的整数;R.sub.1 '和R.sub.2 '独立地是氢、卤素、三氟甲基、较低的烷氧基或较低的烷基;X是嘧啶基、噻唑基或##STR2##,其中R是氢、较低的烷基、芳基或芳基-较低的烷基;要求至少一个R.sub.1 '和R.sub.2 '不是氢,并且它们的药用可接受的酸盐,以及利用式##STR3##的化合物的抗炎方法,其中n是0到2的整数;R.sub.1和R.sub.2独立地是氢、卤素、三氟甲基、硝基、氨基、较低的烷基氨基、二较低烷基氨基、较低的烷氧基或较低的烷基;X是嘧啶基、噻唑基或##STR4##,其中R是氢、较低的烷基、芳基或芳基-较低的烷基;以及它们的药用可接受的酸盐。